Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.

The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.

Selenium supplements do not prevent cancer and may increase certain health risks.

Understanding where cancer cells come from helps create better prevention and treatment methods.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.

Cancer rates are increasing in developed countries, with estrogen, aging, low vitamin D3, and HPV infection as common causes.

A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.

Selenium supplements do not prevent cancer and may have harmful effects.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

Finasteride does not prevent bladder cancer.

Tumor proteins can both promote and suppress cancer, depending on the situation.

Heavy metals like arsenic, cadmium, and lead can increase cancer risk and worsen outcomes.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

β-Sitosterol may help prevent heart disease, cancer, and diabetes, but more human studies are needed.

Adherence to finasteride treatment for prostate issues is generally low.

N13-substituted evodiamine derivatives improved anticancer activity and solubility, showing promise for drug development.

Higher C-peptide levels in African-American men and higher HbA1c levels in Caucasian men are linked to lower PSA levels.

Androgen-driven traits don't predict prostate cancer recurrence.

Dutasteride reduces prostate cancer risk by 23% in high-risk men.

Finasteride significantly reduces prostate cancer risk.

Finasteride may reduce prostate cancer risk.

Some prostate cancers have gene changes that may affect treatment with certain drugs.

Finasteride may improve prostate cancer treatment outcomes.

Certain Dibenzo derivatives may help treat prostate cancer.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

SLCO genes may predict prostate cancer mortality risk, and lifestyle changes improve health in advanced prostate cancer.

Finasteride may help prevent prostate cancer, but more research is needed.

Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.